Emerging Infectious Diseases (Nov 2023)

Racial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA

  • Maura K. Lash,
  • Ned H. Latham,
  • Pui Ying Chan,
  • Mary M.K. Foote,
  • Elizabeth A. Garcia,
  • Matthew F. Silverstein,
  • Marcia Wong,
  • Mark Alexander,
  • Karen A. Alroy,
  • Lovedeep Bajaj,
  • Kuan Chen,
  • James Steele Howard,
  • Lucretia E. Jones,
  • Ellen H. Lee,
  • Julian L. Watkins,
  • Tristan D. McPherson

DOI
https://doi.org/10.3201/eid2911.230814
Journal volume & issue
Vol. 29, no. 11
pp. 2353 – 2357

Abstract

Read online

We assessed tecovirimat treatment equity for 3,740 mpox patients in New York, New York, USA, during the 2022 mpox emergency; 32.4% received tecovirimat. Treatment rates by race/ethnicity were 38.8% (White), 31.3% (Black/African American), 31.0% (Hispanic/Latino), and 30.1% (Asian/Pacific Islander/other). Future public health emergency responses must prioritize institutional and structural racism mitigation.

Keywords